RxDoctor Payments Data

Edo Kaluski, MD

Interventional Cardiology · Sayre, PANPI 1245321249

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.5% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 11.2% — the pattern of someone who eats at a lot of different presentations.

$11,506in general payments, 2019–2025

Across 506 payments — averaging $22.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Medtronic$992
  • Boston Scientific$903
  • Amgen$757
  • plus $5K from 26 others
$235,399in research payments, 2019–2025

Across 76 payments — averaging $3097.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$194K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$23K
  • Amgen$16K
  • Vifor (international) Ltd.$2K

What the payments were for

  • Consulting fees$5004%
  • Grants$550%
  • Travel & lodging$3533%
  • Food & beverage$10,52891%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,506 in reported general payments places this provider in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$179,200
Medicare patients
1,522
Services billed
4,621

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$211,921
JardianceEmpagliflozin114$113,541
EntrestoSacubitril/Valsartan83$96,955
XareltoRivaroxaban57$74,263
Praluent PenAlirocumab19$17,775
BrilintaTicagrelor18$16,712
FarxigaDapagliflozin Propanediol13$9,355
Dofetilide21$4,893
Metoprolol Succinate359$4,647
Atorvastatin Calcium350$4,379
Valsartan139$3,055
Ezetimibe139$3,033
Potassium Chloride118$2,596
Clonidine14$1,685
Diltiazem 24hr Er (Cd)Diltiazem Hcl39$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,022$211,921189 claims
Boehringer IngelheimJardiance$556$113,541114 claims
NovartisEntresto$1,290$96,95583 claims
Johnson & JohnsonXarelto$717$74,26357 claims
AstraZenecaBrilinta, Farxiga$1,206$26,06731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →